EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses

Saad Hanif Abbasi iD, Jesper Hallas iD, Peter Bjødstrup Jensen, Hassan Al-Jasim, Anton Pottegård iD

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70126 ↗

At a glance

Journal article in Basic & Clinical Pharmacology & Toxicology, 2025. Written by Saad Hanif Abbasi and 4 co-authors. Institution: Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Major MEDLINE topics: Pharmacoepidemiology, Anticoagulants, Practice Patterns, Physicians', Ischemic Stroke. Cited 1 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Danmarks Frie Forskningsfond.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The type of prescriber typically fulfils the criteria for confounding, as it is associated both with the exposure (e.g., prescriber types may differ in their choice of first‐line treatment) and with the outcome (as different types of prescribers often treat patients with different disease severity). Additionally, the type of prescriber may correlate with other factors such as treatment adherence, surveillance or coding practices. Although information on the type of prescriber is often available in healthcare registries, it is very rarely employed to control for confounding in pharmacoepidemiological analyses. Here, we argue the potential value in adjusting for the prescriber type in pharmacoepidemiological studies. In an applied example, we conducted a cohort study using Danish healthcare registers of the risk of ischemic stroke associated with the use of direct oral anticoagulants (DOACs) compared to warfarin. We found a hazard ratio (HR) of 0.95 (95% CI: 0.90–1.01) for DOACs versus warfarin when adjusting only for age and sex. Further adjustment for prescriber type showed an effect of similar magnitude (HR 0.92; 95% CI: 0.87–0.98). However, interaction testing and stratified analyses confirmed prescriber type as an effect modifier. Future studies are needed to clarify the role of adjusting for prescriber type across other use cases and healthcare settings.

Subjects

MeSH terms (MEDLINE)

PharmacoepidemiologyAnticoagulantsPractice Patterns, Physicians'Ischemic StrokeHumansMaleFemaleDenmarkWarfarinCohort StudiesRegistriesAgedMiddle Aged

Author keywords

confounder adjustmentconfoundingpharmacoepidemiologyprescriber settingprescriber type

Substances

AnticoagulantsWarfarin

Authors and institutions

  • Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.

ORCID profiles: Saad Hanif Abbasi, Jesper Hallas, Anton Pottegård

Funding

  • Danmarks Frie Forskningsfond

Cite

APA

Abbasi, S. H., Hallas, J., Jensen, P. B., Al-Jasim, H., & Pottegård, A. (2025). Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70126

Vancouver

Abbasi SH, Hallas J, Jensen PB, Al-Jasim H, Pottegård A. Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70126

BibTeX
@article{Abbasi2025,
  author = {Abbasi, Saad Hanif and Hallas, Jesper and Jensen, Peter Bjødstrup and Al-Jasim, Hassan and Pottegård, Anton},
  title = {Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70126}
}
Start for free →